Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil

NCT01357863 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01357863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01357863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Terminated
Start date
July 15, 2010
Completion date
December 13, 2010
Enrollment
3 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

cancer